These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24662788)

  • 1. [Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis].
    Szwed M
    Postepy Hig Med Dosw (Online); 2014 Feb; 68():198-208. PubMed ID: 24662788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.
    Bernitsas E; Wei W; Mikol DD
    Ann Neurol; 2006 Jan; 59(1):206-9. PubMed ID: 16374818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis].
    Feuillet L; Guedj E; Eusebio A; Malikova I; Pelletier J; Mundler O; Ali Chérif A;
    Rev Neurol (Paris); 2003 Dec; 159(12):1169-72. PubMed ID: 14978418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
    Goffette S; van Pesch V; Vanoverschelde JL; Morandini E; Sindic CJ
    J Neurol; 2005 Oct; 252(10):1217-22. PubMed ID: 15834643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mitoxantrone].
    Pericot I; Montalban X
    Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
    Pattoneri P; Pelà G; Montanari E; Pesci I; Moruzzi P; Borghetti A
    Eur J Echocardiogr; 2007 Mar; 8(2):144-50. PubMed ID: 16603413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic role of mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    Pharmacol Ther; 2006 Jan; 109(1-2):198-209. PubMed ID: 16095713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?
    Murray TJ
    Expert Opin Drug Saf; 2006 Mar; 5(2):265-74. PubMed ID: 16503747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitoxantrone treatment of multiple sclerosis: safety considerations.
    Cohen BA; Mikol DD
    Neurology; 2004 Dec; 63(12 Suppl 6):S28-32. PubMed ID: 15623667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone in the treatment of multiple sclerosis.
    Morrissey SP; Le Page E; Edan G
    Int MS J; 2005 Nov; 12(3):74-87. PubMed ID: 16417821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
    Hamzehloo A; Etemadifar M
    Arch Iran Med; 2006 Apr; 9(2):111-4. PubMed ID: 16649351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    Adv Neurol; 2006; 98():293-302. PubMed ID: 16400840
    [No Abstract]   [Full Text] [Related]  

  • 15. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
    Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM
    Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunosuppressive therapy of multiple sclerosis with mitoxantrone].
    Mauch E; Kornhuber HH
    Fortschr Neurol Psychiatr; 1993 Dec; 61(12):410-7. PubMed ID: 8112704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac effects of mitoxanthrone therapy in patients with multiple sclerosis.
    Pastuszak Ż; Tomczykiewicz K; Piusińska-Macoch R; Stępień A
    Kardiol Pol; 2016; 74(4):380-4. PubMed ID: 26412472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.
    Wundes A; Kraft GH; Bowen JD; Gooley TA; Nash RA
    Clin Neurol Neurosurg; 2010 Dec; 112(10):876-82. PubMed ID: 20727669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current role of mitoxantrone in the treatment of multiple sclerosis.
    Cocco E; Marrosu MG
    Expert Rev Neurother; 2014 Jun; 14(6):607-16. PubMed ID: 24834466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.
    Neuhaus O; Wiendl H; Kieseier BC; Archelos JJ; Hemmer B; Stüve O; Hartung HP
    J Neuroimmunol; 2005 Nov; 168(1-2):128-37. PubMed ID: 16171875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.